68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs

Rudolf A Werner; Christina Bluemel; Martin S Allen-Auerbach; Takahiro Higuchi; Ken Herrmann

doi:10.1007/s12149-014-0898-6

68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs

Ann Nucl Med. 2015 Jan;29(1):1-7. doi: 10.1007/s12149-014-0898-6. Epub 2014 Aug 20.

Authors

Rudolf A Werner¹, Christina Bluemel, Martin S Allen-Auerbach, Takahiro Higuchi, Ken Herrmann

Affiliation

¹ Department of Nuclear Medicine, Universitätsklinikum Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.

Abstract

Abundant expression of somatostatin receptors (SSTR) is frequently identified in differentiated neuroendocrine tumors and may serve as potential target for diagnostic imaging and treatment. This article discusses the "theranostic approach" of SSTR-targeting compounds including an overview of its role for diagnosis, staging and restaging, discussing its way to being established in clinical routine, and giving an outlook about further potentially relevant developments.

Publication types

Review

MeSH terms

Gallium Radioisotopes / therapeutic use
Humans
Lutetium / therapeutic use
Neuroendocrine Tumors / diagnostic imaging*
Neuroendocrine Tumors / metabolism
Neuroendocrine Tumors / radiotherapy*
Radioisotopes / therapeutic use
Radionuclide Imaging
Radiopharmaceuticals / therapeutic use*
Receptors, Somatostatin / metabolism
Yttrium Radioisotopes / therapeutic use

Substances

Gallium Radioisotopes
Radioisotopes
Radiopharmaceuticals
Receptors, Somatostatin
Yttrium Radioisotopes
Lutetium